Endocrinology, Vol 137, 2664-2669, Copyright © 1996 by Endocrine Society

ARTICLES

Both the 5' and 3' noncoding regions of the thyrotropin receptor messenger ribonucleic acid influence the level of receptor protein expression in transfected mamalian cells

a Kakinuma, G Chazenbalk, S Filetti, SM McLachlan and B Rapoport
Thyroid Molecular Biology Unit, Veterans' Administration Medical Center, San Francisco, California 94121, USA.

The molecular basis for the difference in the bioresponsiveness of TSH receptor cell lines from two different laboratories has been investigated. We modified our 4-kb TSH receptor complementary DNA (cDNA) by deleting either the 5' untranslated region (UTR), the 3'UTR, or both UTRs. The 5'UTR contains two false AUG initiation codons followed by a stop codon. The cDNAs in the eukaryotic expression vector pSV2-NEO-ECE, as well as the 5'3'UTR-truncated cDNA in pSVL, were stably transfected into Chinese hamster ovary cells. Pools of more than 100 colonies were studied in order to minimize insertion site-dependent variation in the level of expression. Scatchard analysis of TSH binding indicated that the number of receptors on the surface of Chinese hamster ovary cells expressing the wild-type transcript (approximately 16,000/cell) increased approximately 2-fold with 5'UTR deletion, approximately 5-fold with 3'UTR deletion, and approximately 10-fold with both 5'UTR and 3'UTR deletion. TSH binding affinities of all constructs were in the range of 2-5 x 10(-10) M. No significant difference was evident between the 5'3'UTR truncated cDNAs in the two different vectors, pSV2-NEO-ECE and pSVL. The increase in the amplitude of the cAMP response to TSH stimulation was commensurate with the number of receptors expressed on the surface of the different cell lines. Truncation of the 5'UTR did not alter TSH receptor messenger RNA (mRNA) levels relative to the wild-type mRNA. In contrast, the level of the 3'UTR-truncated transcript, as well as the 5'3'UTR-deleted transcript, increased approximately 4-fold independent of the expression vector used. In summary, both the 5'UTR and 3'UTR of the human TSH receptor mRNA influence the level of receptor expression on transfected mammalian cells. In particular, the 3'UTR has a destabilizing influence on the MRNA. These data explain the greater level of TSH receptor expression in cell lines that are transfected with cDNA lacking these regions of the mRNA transcript.

This article has been cited by other articles:

				C.-R. Chen, S. M. McLachlan, and B. Rapoport Suppression of Thyrotropin Receptor Constitutive Activity by a Monoclonal Antibody with Inverse Agonist Activity Endocrinology, May 1, 2007; 148(5): 2375 - 2382. [Abstract] [Full Text] [PDF]

				C.-R. Chen, G. D. Chazenbalk, K. A. Wawrowsky, S. M. McLachlan, and B. Rapoport Evidence that Human Thyroid Cells Express Uncleaved, Single-Chain Thyrotropin Receptors on Their Surface Endocrinology, June 1, 2006; 147(6): 3107 - 3113. [Abstract] [Full Text] [PDF]

				G. D. Chazenbalk, F. Latrofa, S. M. McLachlan, and B. Rapoport Thyroid Stimulation Does Not Require Antibodies with Identical Epitopes But Does Involve Recognition of a Critical Conformation at the N Terminus of the Thyrotropin Receptor A-Subunit J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1788 - 1793. [Abstract] [Full Text] [PDF]

				G. D. Chazenbalk, C.-R. Chen, S. M. McLachlan, and B. Rapoport Does Thyrotropin Cleave Its Cognate Receptor? Endocrinology, January 1, 2004; 145(1): 4 - 10. [Abstract] [Full Text] [PDF]

				C.-R. Chen, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport Evidence that the C Terminus of the A Subunit Suppresses Thyrotropin Receptor Constitutive Activity Endocrinology, September 1, 2003; 144(9): 3821 - 3827. [Abstract] [Full Text] [PDF]

				C.-R. Chen, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport Targeted Restoration of Cleavage in a Noncleaving Thyrotropin Receptor Demonstrates that Cleavage Is Insufficient to Enhance Ligand-Independent Activity Endocrinology, April 1, 2003; 144(4): 1324 - 1330. [Abstract] [Full Text] [PDF]

				P. Pichurin, O. Pichurina, G. D. Chazenbalk, C. Paras, C.-R. Chen, B. Rapoport, and S. M. McLachlan Immune Deviation Away from Th1 in Interferon-{gamma} Knockout Mice Does Not Enhance TSH Receptor Antibody Production after Naked DNA Vaccination Endocrinology, April 1, 2002; 143(4): 1182 - 1189. [Abstract] [Full Text] [PDF]

				G. F. Mao, V. R. Vaidyula, S. P. Kunapuli, and A. K. Rao Lineage-specific defect in gene expression in human platelet phospholipase C-beta 2 deficiency Blood, February 1, 2002; 99(3): 905 - 911. [Abstract] [Full Text] [PDF]

				P. Pichurin, X.-M. Yan, L. Farilla, J. Guo, G. D. Chazenbalk, B. Rapoport, and S. M. McLachlan Naked TSH Receptor DNA Vaccination: A TH1 T Cell Response in Which Interferon-{gamma} Production, Rather than Antibody, Dominates the Immune Response in Mice Endocrinology, August 1, 2001; 142(8): 3530 - 3536. [Abstract] [Full Text] [PDF]

				K. Tanaka, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport Evidence that Cleavage of the Thyrotropin Receptor Involves a "Molecular Ruler" Mechanism: Deletion of Amino Acid Residues 305-320 Causes a Spatial Shift in Cleavage Site 1 Independent of Amino Acid Motif Endocrinology, October 1, 2000; 141(10): 3573 - 3577. [Abstract] [Full Text] [PDF]

				G. D. Chazenbalk, K. Tanaka, S. M. McLachlan, and B. Rapoport On the Functional Importance of Thyrotropin Receptor Intramolecular Cleavage Endocrinology, October 1, 1999; 140(10): 4516 - 4520. [Abstract] [Full Text]

				J. C. Jaume, J. Guo, Y. Wang, B. Rapoport, and S. M. McLachlan Cellular Thyroid Peroxidase (TPO), Unlike Purified TPO and Adjuvant, Induces Antibodies in Mice That Resemble Autoantibodies in Human Autoimmune Thyroid Disease J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1651 - 1657. [Abstract] [Full Text]

				K. Tanaka, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport Thyrotropin Receptor Cleavage at Site 1 Involves Two Discontinuous Segments at Each End of the Unique 50-Amino Acid Insertion J. Biol. Chem., January 22, 1999; 274(4): 2093 - 2096. [Abstract] [Full Text] [PDF]

				B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text]

				A. Kakinuma, G. D. Chazenbalk, K. Tanaka, Y. Nagayama, S. M. McLachlan, and B. Rapoport An N-Linked Glycosylation Motif from the Noncleaving Luteinizing Hormone Receptor Substituted for the Homologous Region (Gly367 to Glu369) of the Thyrotropin Receptor Prevents Cleavage at Its Second, Downstream Site J. Biol. Chem., November 7, 1997; 272(45): 28296 - 28300. [Abstract] [Full Text] [PDF]

				J. Parma, L. Duprez, J. Van Sande, J. Hermans, P. Rocmans, G. Van Vliet, S. Costagliola, P. Rodien, J. E. Dumont, and G. Vassart Diversity and Prevalence of Somatic Mutations in the Thyrotropin Receptor and Gs{alpha} Genes as a Cause of Toxic Thyroid Adenomas J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2695 - 2701. [Abstract] [Full Text] [PDF]

				G. D. Chazenbalk, J. C. Jaume, S. M. McLachlan, and B. Rapoport Engineering the Human Thyrotropin Receptor Ectodomain from a Non-secreted Form to a Secreted, Highly Immunoreactive Glycoprotein That Neutralizes Autoantibodies in Graves' Patients' Sera J. Biol. Chem., July 25, 1997; 272(30): 18959 - 18965. [Abstract] [Full Text] [PDF]

				A. Kakinuma, G. D. Chazenbalk, J. C. Jaume, B. Rapoport, and S. M. McLachlan The Human Thyrotropin (TSH) Receptor in a TSH Binding Inhibition Assay for TSH Receptor Autoantibodies J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2129 - 2134. [Abstract] [Full Text] [PDF]

				G. D. Chazenbalk, K. Tanaka, Y. Nagayama, A. Kakinuma, J. C. Jaume, S. M. McLachlan, and B. Rapoport Evidence That the Thyrotropin Receptor Ectodomain Contains Not One, But Two, Cleavage Sites Endocrinology, July 1, 1997; 138(7): 2893 - 2899. [Abstract] [Full Text] [PDF]

				J. C. Jaume, A. Kakinuma, G. D. Chazenbalk, B. Rapoport, and S. M. McLachlan Thyrotropin Receptor Autoantibodies in Serum Are Present at Much Lower Levels Than Thyroid Peroxidase Autoantibodies: Analysis by Flow Cytometry J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 500 - 507. [Abstract] [Full Text] [PDF]

				C.-R. Chen, K. Tanaka, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport A Full Biological Response to Autoantibodies in Graves' Disease Requires a Disulfide-bonded Loop in the Thyrotropin Receptor N Terminus Homologous to a Laminin Epidermal Growth Factor-like Domain J. Biol. Chem., April 27, 2001; 276(18): 14767 - 14772. [Abstract] [Full Text] [PDF]